Cannabis
& Stress/Anxiety
In
recent IDMU surveys, relaxation and stress relief were
overwhelmingly the most commonly perceived benefits
of cannabis use. However, the Department of Health
identifies panic attacks and anxiety as effects of acute
cannabis intoxication, particularly among naive users,
in justifying the refusal of the UK Government to permit
the prescribing of cannabis..
Recent
advances in fundamental cannabinoid research have been
interpreted as indicating a common modality of action
of cannabis and opiate drugs, in that naloxone (an opiate
antagonist) blocks cannabinoid-induced dopamine release
in the limbic system (a primitive brain structure associated
with control of emotion and mood) [i] and the a cannabinoid antagonist administered
to rats, pretreated with a powerful synthetic cannabinoid
agonist, can precipitate corticotrophin releasing factor
(CRF) which is held to be the mechanism responsible
for mediating the psychological aspects of drug withdrawal
symptoms, and leading to anxiety-type behaviours
[ii] . This was interpreted as demonstrating
a cannabis withdrawal syndrome, however the potency
of the synthetic cannabinoid used was many times that
of THC, and the administration of an antagonist (blocker)
would not effectively mimic the gradual decrease in
plasma THC which occurs with cessation of normal use.
The fact that a potent cannabis blocker caused anxiety
symptoms in rats would be consistent with a general
diminution of anxiety levels arising from cannabis use.
Laurie
[iii] reported that in a few cases 'anxiety,
which may approach panic, often associated with a fear
of death or an oppressive foreboding is infrequently
seen, usually giving way to an increasing sense of calmness...
to euphoria'. Grinspoon refers to the initial
state as a 'happy anxiety' where the experience is internally
redefined as pleasurable. Rosenthal et al
[iv] report that panic reactions and anxiety
are rare, and most commonly found with overdose (particularly
from oral preparations), in na¹ve users, or in those
who do not like the effects of marijuana, and attributed
the incidence of anxiety reports with Marinol (dronabinol
- pure THC) to the lack of CBD within the preparation.
Mikuriya
[v] considered that 'the power of cannabis
to fight depression is perhaps its most important property'.
Patients were reported to self-medicate with cannabis
rather than use benzodiazepines as the former produced
less dulling of mental activity. The authors cited
one study where marijuana was found to increase anxiety
in na¹ve users, but to decrease anxiety in experienced
users, and another of 79 psychotics who used marijuana
recreationally and reported less anxiety, depression,
insomnia or physical discomfort
[vi] , and concluded that natural marijuana
- containing CBD and THC - appeared more effective than
THC alone in treating depression, and that patients
suffering stress as a result of pain or muscle spasms
would be most likely to be helped by the drug.
They differentiated the use of cannabis to cope with
everyday life stresses from the use of benzodiazepines
in treating 'severe anxiety disorders' with an organic
aetiology.
Bello
[vii] in a passionate treatise on the benefits
of cannabis for physical and mental health, likened
the anxiolytic effect of marijuana to a state of relaxed
alertness brought on by 'balancing' the autonomic nervous
system.
Explanations
of the panic and anxiety experienced by some na¹ve users
exposed to cannabis would include 'set and setting'
i.e. a drug taken in the course of a laboratory experiment
would provide different expectations of an experience
to an informal party or gathering of friends, secondly
the increase in heart rate can be interpreted by some
older users as a heart attack and cause panic attacks
[viii] , this 'tachycardia' is normally associated
with a reduction in blood pressure, the combined effect
is analogous to changing down a gear in a motor vehicle.
Some individuals may be more susceptible to the effects
of cannabis than others, and those whose initial experience
is unpleasant may be more likely to discontinue use
of the drug. By contrast, many first-time users
fail to notice the influence of the drug.
Thompson
& Proctor [ix] , treating withdrawal conditions, noted the synthetic
cannabinoid pyrahexyl to produce significant increases
in alpha brain waves, indicating increased relaxation,
and Adams reported similar results [x] . However Williams et al
found no significant increase in alpha activity either
with parahexyl or smoked marijuana [xi] .
Davies
et al
[xii] , in a study of cancer patients, considered
the management of stressful patients to have been improved
by oral THC. However a study of intravenous THC
used as a premedication for oral-facial surgery [xiii] found that patients showed
pronounced elevation of anxiety, and considered noxious
stimuli to be more painful. Mechoulam [xiv] considered a number of synthetic cannabinoids
to be worthy of investigation as potential sedative-relaxants.
In
laboratory animals, the cannabinoid receptor has been
linked to modulation of emotional behaviour [xv] , reinforcement [xvi] , learning
[xvii] and memory [xviii]
[xix] Musty [xx] compared the
effects of THC, CBD (cannabidiol) and diazepam (valium)
on anxiety-related behaviours in mice. THC
produced similar reductions in anxiety behaviours to
diazepam, however the effect of CBD was more pronounced
than either in measures of shock-avoidance, grooming
and reduction of delerium tremens in alcohol-withdrawn
mice. Both THC and CBD produced dose-related reductions
in ulcer formation in stressed mice. However in
all tests the CBD dosages used were higher than THC
dosages.
Mechoulam
reviewed studies of Nabilone (synthetic cannabinoid)
on anxiety, finding two studies which suggested a superior
effect on anxiety, mood and concomitant depression,
whereas two other studies found little or no effect.
Benowitz & Jones
[xxi] reported initial tachycardia and hypertension
in volunteer subjects administered up to 210mg THC per
day, but found development of tolerance to tachycardia
and CNS effects over the 20 day experiment, with blood
pressure reduced and stabilised at around 95/65.
Fabre & McLendon [xxii] reported a dramatic improvement
in anxiety in the nabilone-treated group compared to
placebo. Nakano et al
[xxiii] reported anti anxiety effects of
nabilone and diazepam in a controlled trial of experimentally-induced
stress, but was unable to conclude which was more effective
due to differences in dosage and metabolism. Hollister [xxiv] reported these
and other nabilone studies [xxv] indicating significant
anti-anxiety effects of low doses, and commented on
the scarcity of studies of potential anti-anxiety effects
of cannabinoids.
Post-Traumatic
Stress Disorder: I am unaware of any controlled
scientific studies in published journals which investigate
the use of cannabis as a treatment option for post-traumatic
stress disorder, although several studies of this condition
make reference to cannabis use by patients. In
a study of female drug clinic patients with histories
of post-traumatic stress disorder following physical
or sexual abuse, Gil-Revas et al [xxvi] reported "contrary
to expectation, PTSD is not associated with relapse
to drug use". Clark et al
[xxvii] found PTSD to be a common diagnosis
among a group of alcoholic adolescents, who also showed
high rates of cannabis and hallucinogen use, considering
the relationship to reflect a comorbid disorder.
DeFazio et al [xxviii] studied Vietnam veterans,
finding a higher incidence of PTSD symptoms among combat,
compared to non-combat groups, the relationship to cannabis
use is unclear, but may reflect a coping strategy, where
the use of marijuana by US troops during combat has
been widely-documented, which typically ceased upon
return to civilian life.
Cannabis
and Depression
Depression
is a term used to describe a variety of different disorders
characterised by lowering of mood, disinterest in ones
surroundings or condition, fatigue, and loss of appetite
and/or personal neglect. For most people, depression
is a passing mood, for others it is a debilitating condition
with severe emotional and physical symptoms. Only
when depression is serious is it normally considered
a psychiatric disorder requiring treatment. Most
drug treatments for clinical depression involve use
of tricyclic antidepressants (e.g. amitriptyline), monoamine
oxidase inhibitors (e.g. isocarboxazid) or more recently
fluotexine (prozac), both of which boost levels of brain
catecholamines (stimulant neurotransmitters including
noradrenalin or serotonin).
Cannabis
products have long been considered to be effective in
the treatment of depressive disorders, in 1845 it was
recommended for melancholia (with obsessive rumination)
and mental disorder in general [xxix] . In 1947
Stockings
[xxx] found improvements in 36 out of 50
depressed mental patients treated with a synthetic cannabinoid.
Grant et al
[xxxi] in a US population study, commented
"cannabis might be
used to self-medicate major depression."
Schnelle et al
[xxxii] found depression to be the most
common reason for self-medication in a study of German-speaking
medicinal cannabis patients.
In
a case study Bolls [xxxiii] reported a case of post-natal
depression successfully treated by a large oral dose
(4g of alcoholic cannabis tincture) and counselling.
The subject reported anxiety at the peak of the drugs
effect, however the study involved a single case, was
not controlled under current scientific methodology,
and it could not now be concluded whether any recovery
was due to the drug, the psychotherapy, or would have
occurred in any event. Conversely Payne
[xxxiv] reported a case history where cannabis
use was considered to worsen the patientòs mood disorder.
Kotin
et al
[xxxv] , in a double-blind experiment, found
no effect on moderate to severe depression from relatively
high doses (0.3mg/kg) of THC. Grinspoon considered
cannabinoids to be of promise where depression is secondary
to some life event (reactive depression) rather than
a primary diagnosis, but did not consider general optimism
about such treatment to be justified by the state of
knowledge in 1977.
Regelson
et alia
[xxxvi] reported a number of significant
effects in a controlled study of THC in terminal cancer
patients, including a reduction in depression, greater
emotional stability, more self-reliant/less dependent,
less suspiciousness, increased forthrightness, less
apprehension, more normal level of control and more
tranquil/relaxed, however two patients who discontinued
the study reported fear and anxiety, confused thinking
and dissociation. The authors commented that such
effects would appear to be confined to a susceptible
population.
Grinspoon
[xxxvii] considered some patients who fail
to respond to traditional antidepressant drugs, or who
find the side-effects of these unbearable, to have been
helped by illicit marijuana use, quoting 3 case studies
all involving long histories of severe clinical depression,
all treated unsuccessfully with all types of antidepressive
medication, and all now living normally through use
of cannabis, twice daily in one case, on re-appearance
of symptoms in the others, each attributing the improvement
to greater self-insight, a reduction of a negative self-image,
and/or a general euphoria arising from cannabis intoxication.
Several
recent studies have highlighted the association between
depression, conduct disorder and substance (including
cannabis & alcohol) abuse [xxxviii] . Rey et al [xxxix] considered
this to represent "a
malignant pattern of comorbidity that may lead to negative
outcomes". Lynskey et al
[xl] noted major depression to be a correlate
of cannabis dependence, but noted "genetic risk factors are important determinants of
risk of cannabis dependence among men". Bovasso
[xli] , following a large-scale longitudinal
survey of depressive patients, considered cannabis
use to be a risk factor for depressive symptoms:
"In participants with no baseline depressive symptoms,
those with a diagnosis of cannabis abuse at baseline
were four times more likely than those with no cannabis
abuse diagnosis to have depressive symptoms at the follow-up
assessment, after adjusting for age, gender, antisocial
symptoms, and other baseline covariates. In particular,
these participants were more likely to have experienced
suicidal ideation and anhedonia during the follow-up
period. Among the participants who had no diagnosis
of cannabis abuse at baseline, depressive symptoms at
baseline failed to significantly predict cannabis abuse
at the follow-up assessment." In a case study
of a brain-damaged patient, Payne [xlii] noted "The
impact of cannabis use in this individual appeared to
have a detrimental effect on his mood."
In
a survey of young Austrialian adults, Degenhardt et
al
[xliii] concluded "Cannabis
use did not appear to be directly related to depression
or anxiety when account was taken of other drug use.
However, the association between heavier involvement
with cannabis use and affective and anxiety disorders
has implications for the treatment of persons with problematic
cannabis use." Dhossche et al
[xliv] noted "Detection
of alcohol, cocaine, or cannabis in about 40% of suicides
supports the clinical practice of discouraging consumption
of these substances in depressed patients".
However in a clinical trial of synthetic cannabinoids
(CB1-agonists) Tramer et al found these enhanced mood
among cancer patients: "In
selected patients, the cannabinoids tested in these
trials may be useful as mood enhancing adjuvants for
controlling chemotherapy related sickness."
[xlv] Nunn et al
[xlvi] reported "Neither
anxiety or depression scores were higher in cannabis
users...", and Dumas et al
[xlvii] reported "The
co-occurrence of cannabis use and schizotypal traits
appeared to be independent of anxiety and depression
dimensions".
However
Aharonovitch et al [xlviii] postulated "the
self-medication hypothesis of substance abuse...
that drug abuse is driven by an attempt to alleviate
specific psychological distress". Abraham
& Fava
[xlix] studying the order of onset
of depression and substance abuse in an attempt
to resolve the "cause or self-medicationò question,
reached no conclusions concerning cannabis alone, but
noted "Among polydrug-dependent
patients, each drug abused followed the onset of depression,
except for LSD, which coincided with the onset of depression."
In a study of patients with bipolar disorder (manic
depressive psychosis), Strakowski et al [l] found "The
duration of alcohol abuse during follow-up was associated
with the time patients experienced depression. The duration
of cannabis abuse was associated with the duration of
mania." In schizophrenia patients,
Hambrecht & Hafner [li] identified three subtypes of patient in
relation to cannabis use: "Group
1 might suffer from the chronic deteriorating influence
of cannabis reducing the vulnerability threshold and/or
coping resources. Group 2 consists of individuals which
are already vulnerable to schizophrenia. Cannabis misuse
then is the (dopaminergic) stress factor precipitating
the onset of psychosis. Group 3 uses cannabis for self-medication
against (or for coping with) symptoms of schizophrenia,
particularly negative and depressive symptoms. These
patients probably learn to counterbalance a hypodopaminergic
prefrontal state by the dopaminergic effects of cannabis."
In an American epidemiological study of cannabis use,
dependence and co-morbidity, Grant & Pickering
[lii] concluded "cannabis
might be used to self-medicate major depression."
A
Canadian study of self-medicating cannabis users by
Ogborne et al [liii] reported patients
used for a variety of conditions including: "HIV-AIDS-related problems, chronic pain, depression,
anxiety, menstrual cramps, migraine, narcotic addiction
as well as everyday aches, pains, stresses and sleeping
difficulties." In a similar German
study, Schnelle et al
[liv] found "The
most frequently mentioned indications for medicinal
cannabis use were depression (12.0%), multiple sclerosis
(10.8%), HIV-infection (9.0%), migraine (6.6%), asthma
(6.0%), back pain (5.4%), hepatitis C (4. 8%), sleeping
disorders (4.8%), epilepsy (3.6%), spasticity (3.6%),
headache (3.6%), alcoholism (3.0%), glaucoma (3.0%),
nausea (3.0%), disk prolapse (2.4%), and spinal cord
injury (2.4%)."
In
a learned review, Williamson & Evans [lv] reported "Not
all the observed effects can be ascribed to THC, and
the other constituents may also modulate its action;
for example CBD reduces anxiety induced by THC. A standardised
extract of the herb may be therefore be more beneficial
in practice and clinical trial protocols have been drawn
up to assess this." and concluded "Patients taking the synthetic derivative nabilone
for neurogenic pain actually preferred cannabis herb
and reported that it relieved not only pain but the
associated depression and anxiety."
In
November 2002, the British Medical Journal published
the results of three separate longitudinal ("cohortò)
studies into mental health outcomes of adolescent cannabis
users.
(a)
Swedish Conscripts
¸ a cohort study by Zammitt et al [lvi] of 50,000 Swedish
male conscripts in 1969 were followed up at intervals
between 1970 and 1996. Of the 5391 subjects who
had ever used cannabis, 73 had developed schizophrenia
(1.4%) compared to 215 out of 36429 subjects (0.6%)
who had never used (or denied using) the drug.
The study suggested that all cannabis users are 50%
more likely to develop schizophrenia, and regular users
three times as likely, after controlling for social
factors including use of other drugs. However
the study had data on cannabis use only at the outset
of the study, and the control cohort would not have
excluded subjects who subsequently started to use cannabis
after age 18-20, or users of cannabis who denied using
the drug. It is unclear whether the rigour
in assessing the mental health history of control subjects
matched that for cannabis-using subjects.
(b)
Australian Students
¸ A seven year follow-up study of 1601 secondary school
students in Australia by Patton et al [lvii] found that weekly or more frequent use of cannabis
during adolescence predicted a two-fold increase in
later development of depression and anxiety, with young
women being at particular risk, although for young men
the effect was not statistically significant, if anything
they showed lower rates of depression than controls.
Young women were statistically 60% more likely to develop
depression than men in the absence of cannabis use.
The authors found no relationship between adolescent
anxiety and depression and later cannabis use, which
they interpreted as excluding the "self-medicationò
hypothesis.
(c)
New Zealand Birth Cohort
¸ A longitudinal study by Arsenault et al [lviii] of 1037 individuals
born in 1972-3 was followed up at ages 11, 15, 18 and
26. They found cannabis use by age 15 (n=29) to
be associated with a four-fold increase in the likelihood
of developing schizophreniform symptoms by age 26 (p<.05),
although use by age 18 (n=236) showed no significantly
increased risk. A weakly significant association
was found between cannabis use by age 18 and depressive
symptoms by age 26, the odds ratio falling closer to
the boundary of significance when the data was controlled
for pre-existing psychopathologies and use of other
drugs. Again, no relationship was found between
adolescent symptomatology and later cannabis use, and
the authors rejected the "self-medicationò hypothesis.
It
may well be that common factors predispose an individual
both to schizophrenia and to early use of cannabis,
particularly in a country like Sweden with a very strong
prohibitionist enforcement policy and anti-drug social
attitudes, where early cannabis use may be considered
more "deviantò than in countries with more tolerant
social attitudes to the drug.
[i]Tanda G, Pontieri FE & Di Chiara
G (1997) Cannabinoid and heroin activation of the
mesolimbic dopamine transmission oy a common µ1
opioid receptor mechanism. Science 276 pp2048-2050
[ii]de Fonseca FR, Carrera MRA, Navarro
M, Koob G & Weiss F (1997) Activation of the corticotropin
releasing factor in the limbic system during cannabinoid
withdrawal Science 276 pp2050-2054
[iii] Laurie P (1967)
Drugs: Medical, psychological and social facts.
London: Penguin
[iv] Rosenthal E, Mikuriya
TH & Gieringer D (1997) Marijuana Medical
Handbook. Oakland: Quick American Archives
[vii] Bello J (1997)
The benefits of marijuana physical, psychological
and spiritual Cottonwood CA; Sweetlight
Books
[viii] Weil A (1972) The
Natural Mind Boston: Houghton Mifflin
p76
[ix] Thompson LJ &
Proctor RC (1953) Pyrahexyl in the treatment of drug
and alcoholic withdrawal conditions. North Carolina
Medical Journal 14 p321 - Cited Grinspoon L (1977)
Marijuana Reconsidered. Harvard University Press
[x] Adams R (1942) Marijuana
Harvey Lectures 36 pp168-197 - Cited Grinspoon L (1977)
Marijuana Reconsidered. Harvard University Press
[xi]Williams EG et al (1946) Studies on
Marijuana and Pyrahexyl compound. Public Health
Reports 61 pp1064-1074 - Cited Grinspoon L (1977)
Marijuana Reconsidered. Harvard University Press
[xii] Davies BH, Weatherstone
RM, & Graham JDP (1974) A pilot study of
orally administered delta nine trans THC in the management
of patients undergoing radiotherapy for carcinoma
of the bronchus. British Journal of Clinical
Pharmacology 1 pp301-306
[xiii] Gregg JM, Small
EW, & Moore R (1976) Emotional respose to intravenous
delta-9-tetrahydrocannabinol during oral surgery.
Journal of Oral & Maxillofacial Surgery 34(4)
pp301-313
[xiv] Mechoulam R &
Carlini EA (1978) Naturwissenschaften 65(4)
pp174-179
[xv] Martin M, Ledent C, Parmentier M, Maldonado
R, Valverde O. [2002] Involvement of CB1 cannabinoid
receptors in emotional behaviour. Psychopharmacology
(Berl)159(4):379-87
[xvi] Deroche-Gamonet V, Le Moal M, Piazza PV, Soubrie
P. [2001] SR141716, a CB1 receptor antagonist, decreases
the sensitivity to the reinforcing effects of electrical
brain stimulation in rats. Psychopharmacology (Berl)
157(3):254-9
[xvii] Presburger G,
Robinson JK [1999] Spatial signal detection
in rats is differentially disrupted by delta-9-tetrahydrocannabinol,
scopolamine, and MK-801 Behav Brain Res 99(1):27-34
[xviii] Ferrari F, Ottani
A, Vivoli R, Giuliani D [1999] Learning impairment
produced in rats by the cannabinoid agonist HU 210
in a water-maze task. Pharmacol Biochem Behav 64(3):555-61
[xix] Sullivan JM [1999] Mechanisms of cannabinoid-receptor-mediated
inhibition of synaptic transmission in cultured hippocampal
pyramidal neurons J Neurophysiol 82(3):1286-94
[xx] Musty RE (1984)
Possible anxiolytic effects of cannabidiol.
in Agurell S, Dewey WL & Willette RE (Eds) The
Cannabinoids: Chemical, Pharmacologic and Therapeutic
Aspects. Academic Press.
[xxi] Benowitz NL &
Jones RT (1977) Clin Pharmacol Ther 21 p336, cited
Mechoulam (1978) op cit
[xxii] Fabre LF &
McLendon D (1981) The efficacy and safety of Nabilone
(a synthetic cannabinoid) in the treatment of anxiety.
Journal of Clinical Pharmacology 21 (cannabinoids
supplement) pp 377S-382S
[xxiii] Nakano S, Gillespie
HK, & Hollister LE (1978) A model for evaluation
of antianxiety drugs with the use of experimentally
induced stress: Comparison of nabilone and diazepam,
Clinical Pharmacology & Therapeutics 23(1) pp54-62
[xxiv] Hollister LE
(1984) THC as a sedative, hypnotic and muscle relaxant.
Ch. in Harvey DJ, Paton W & Nahas GG (1984 Eds)
Marijuana 84 - proceedings of the Oxford symposium
on cannabis. Oxford: IRL
[xxv] Glass RM,
Uhlenhuth EH, Hartel FW, Schuster CR & Fischman
MW (1981) Journl of Clinical Pharmacology 21
(383S-396S) - cited Hollister 1984 op cit
[xxvi] Gil-Rivas V,
Fiorentine R, Anglin MD (1996) Sexual abuse,
physical abuse, and posttraumatic stress disorder
among women participating in outpatient drug abuse
treatment. J Psychoactive Drugs 28(1):95-102
[xxvii]Clark DB, Pollock N, Bukstein OG,
Mezzich AC, Bromberger JT, Donovan JE (1997)
Gender and comorbid psychopathology in adolescents
with alcohol dependence. J Am Acad Child Adolesc
Psychiatry 36(9):1195-203
[xxviii] DeFazio
VJ, Rustin S, Diamond A (1975) Symptom development
in Vietnam era veterans. Am J Orthopsychiatry
45(1):158-63
[xxix]Moreau-de-Tours JJ (1845) Lypemanie
aver stupeur; tendence a la demence, traitement par
l'extrait (principe resineux) de cannabis indica -Guerison.
Lancette Gazette Hopital 30 p391 (cited Grinspoon
& Bakalar 1993)
[xxx]Stockings GT (1947) A new euphoriant
for depressive mental states. British Medical
Journal 1 pp918-922
[xxxi] Grant BF, Pickering
R (1998) The relationship between cannabis use and
DSM-IV cannabis abuse and dependence: results from
the National Longitudinal Alcohol Epidemiologic Survey.
J Subst Abuse 1998;10(3):255-64
[xxxii] Schnelle M,
Grotenhermen F, Reif M, Gorter RW (1999) [Results
of a standardized survey on the medical use of cannabis
products in the German-speaking area]. [Article in
German] Forsch Komplementarmed 1999 Oct;6 Suppl 3:28-36
[xxxiii] Bolls EJ &
Stafford-Clark D (1954) Depersonalisation treated
by Cannabis Indica and Psychotherapy. Guys Hospital
Reports 103 pp330-336
[xxxiv]Payne HC (2000) Traumatic
brain injury, depression and cannabis use--assessing
their effects on a cognitive performance.
Brain Inj 14(5):479-89
[xxxv] Kotin J. Post
RM & Goodwin FK (1973) Delta-9-tetrahydrcannabinol
in depressed patients. Arch Gen Psychiat 28
pp345-348 - cited Grinspoon L 1977 op cit
[xxxvi]Regelson , Butler JR, Schulz J,
Kirk T, Peek L, Green ML & Zalis MO (1976)
D9 Tetrahydrocannabinol as an effective antidepressant
and appetite stimulating agent in advanced cancer
patients. Ch. in Braude M & Szara S (Eds)
The Pharmacology of Marijuana New York: Raven
Press
[xxxvii] Grinspoon L
& Bakalar JB (1993) Marijuana - the forbidden
medicine. Yale University Press
[xxxviii]Hatzitaskos P, Soldatos CR, Kokkevi
A, Stefanis CN. [1999] Substance abuse patterns
and their association with psychopathology and type
of hostility in male patients with borderline and
antisocial personality disorder. Compr Psychiatry
40(4):278-82
[xxxix]Rey JM, Sawyer MG, Raphael B, Patton GC, Lynskey
M [2002] Mental health of teenagers who use cannabis.
Results of an Australian survey. Br J Psychiatry 180:216-21
[xl]Lynskey MT, Heath AC, Nelson EC, Bucholz KK,
Madden PA, Slutske WS, Statham DJ, Martin NG. [2002]
Genetic and environmental contributions to cannabis
dependence in a national young adult twin sample.
Psychol Med 32(2):195-207
[xli] Bovasso GB. [2001]
Cannabis abuse as a risk factor for depressive symptoms.
Am J Psychiatry 158(12):2033-7
[xlii]Payne HC. [2000] Traumatic brain
injury, depression and cannabis use--assessing their
effects on a cognitive performance. Brain Inj
14(5):479-89
[xliii]Degenhardt L, Hall W, Lynskey M
[2001] The relationship between cannabis use, depression
and anxiety among Australian adults: findings from
the National Survey of Mental Health and Well-Being.
Soc Psychiatry Psychiatr Epidemiol 36(5):219-27
[xliv] Dhossche DM,
Rich CL, Isacsson G [2001] Psychoactive substances
in suicides. Comparison of toxicologic findings in
two samples. Am J Forensic Med Pathol 22(3):239-43
[xlv] Tramer MR,
Carroll D, Campbell FA, Reynolds DJ, Moore RA, McQuay
HJ. [2001] Cannabinoids for control of chemotherapy
induced nausea and vomiting: quantitative systematic
review. BMJ 323(7303):16-21
[xlvi]Nunn JA, Rizza F, Peters ER
[2001] The incidence of schizotypy among cannabis
and alcohol users.J Nerv Ment Dis 189(11):741-8
[xlvii] Dumas P, Saoud M, Bouafia S, Gutknecht C,
Ecochard R, Dalery J, Rochet T, d'Amato T. [2002]
Cannabis use correlates with schizotypal personality
traits in healthy students. Psychiatry Res 109(1):27-35
[xlviii]Aharonovich E, Nguyen HT, Nunes
EV [2001] Anger and depressive states among
treatment-seeking drug abusers: testing the psychopharmacological
specificity hypothesis. Am J Addict 10(4):327-34
[xlix]Abraham HD, Fava M [1999] Order of
onset of substance abuse and depression in a sample
of depressed outpatients.Compr Psychiatry 40(1):44-50
[l] Strakowski SM, DelBello
MP, Fleck DE, Arndt S [2000] The impact of substance
abuse on the course of bipolar disorder. Biol Psychiatry
48(6):477-85
[li] Hambrecht M, Hafner H [2000] Cannabis, vulnerability,
and the onset of schizophrenia: an epidemiological
perspective. Aust N Z J Psychiatry 34(3):468-75
[lii]Grant BF, Pickering R [1998]
The relationship between cannabis use and DSM-IV cannabis
abuse and dependence: results from the National Longitudinal
Alcohol Epidemiologic Survey. J Subst Abuse 10(3):255-64
[liii] Ogborne AC, Smart
RG, Weber T, Birchmore-Timney C. [2000] Who is using
cannabis as a medicine and why: an exploratory study.
J Psychoactive Drugs 32(4):435-43
[liv] Schnelle M, Grotenhermen
F, Reif M, Gorter RW. [1999] [Results of a standardized
survey on the medical use of cannabis products in
the German-speaking area] [Article in German]
Forsch Komplementarmed 6 Suppl 3:28-36
[lv]Williamson EM, Evans FJ
[2000] Cannabinoids in clinical practice. Drugs 60(6):1303-14
[lvi] Zammitt S, Allebeck
P, Andreasson S, Lundberg I & Lewis G [2002]
Self-reported cannabis use as a risk factor for schizophrenia
in Swedish conscripts of 1969: historical cohort study.
British Medical Journal 325 pp1199-1201
[lvii] Patton GC, Coffey
C, Carlin JB, Degenhard L, Lynskey M & Hall W
[2002] Cannabis use and mental health in young
people ¸ cohort study British Medical Journal 325
pp1195-98
[lviii] Arsenault L,
Cannon M, Poulton R, Murray R, Caspi A & Moffitt
TE [2002] Cannabis use in adolescence and risk
for adult psychosis: longitudinal prospective study.